Loading clinical trials...

Annexin A5 in Patients With Severe COVID-19 Disease | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT04748757

Annexin A5 in Patients With Severe COVID-19 Disease

Randomized, double-blind, placebo-controlled trial comparing 2 doses of SY-005 (recombinant human Annexin A5) to placebo in patients with severe coronavirus 2019 disease in a single hospital centre wi...

Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITING

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

NCT06517810 · Acute Kidney Injury, Acute Kidney Injury Due to Sepsis

RECRUITING

Validation of SOFA-2 for Mortality and Sepsis-3 Prevalence in Turkey

NCT07300306 · Sepsis, Septic Shock, and more

RECRUITINGPhase 4

Aminoglycosides in Early Sepsis

NCT06712641 · Sepsis

RECRUITINGPhase 3

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287 · Long COVID, Sars-CoV-2 Infection, and more

RECRUITING

ACOD1 as a Prognostic Marker for Sepsis

NCT07533994 · Sepsis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 8, 2023Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment18

Start dateApr 2021

Last updatedMar 8, 2023

Condition

Coronavirus Infection Sepsis

Locations shown

London Health Sciences Centre

London, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 8, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Annexin A5 in Patients With Severe COVID-19 Disease

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

Validation of SOFA-2 for Mortality and Sepsis-3 Prevalence in Turkey

Aminoglycosides in Early Sepsis

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

ACOD1 as a Prognostic Marker for Sepsis

Trial snapshot

Condition

Locations shown

For caregivers